Screening Eligibility: Men and women 18+ years old, with diagnosis of Extensive Stage Small Cell Lung Cancer, no history of Limited Stage Small Cell Lung Cancer, can either have received no frontline induction therapy with platinum plus etoposide in combination with durvalumab or has received no more than 3 cycles of induction therapy with platinum plus etoposide in combination with durvalumab, and available biopsy tumor tissue.
Based on the results of the screening testing, eligibility will be assessed for study participation.
